Content
and Copyright
i
Superseded
This Document Has Been Replaced By:
i
Retired
This Document Has Been Retired
i
Up-to-date Information
This is the latest update:
Healthcare professionals warned not to use certain intravenous metronidazole, ondansetron, and ciprofloxacin due to potential contamination
-
Published Date:
6/1/10
-
Series:HAN ; 314
-
Language:English
-
[PDF-611.60 KB]
Details:
-
Corporate Authors:
-
Description:Tuesday, June 01, 2010, 10:25 EST (10:25 AM EST) CDCHAN-00314-2010-06-01-ADV-N The U.S. Food and Drug Administration (FDA) is alerting healthcare professionals not to use certain intravenous (IV) bags of metronidazole, ondansetron, and ciprofloxacin because of potential contamination. FDA has received reports of floating matter in IV bags manufactured by Claris Lifesciences Limited, in Ahmedabad, India. Microbiological analysis identified the matter in one of the bags as a Cladosporium mold. Molds of this type can cause infections in susceptible patients, such as immunocompromised individuals. At this time, FDA is not aware of any reports of injuries due to administration of these products. Affected products include any metronidazole, ondansetron, and ciprofloxacin manufactured by Claris Lifesciences Limited and sold under the following labels: Claris, Sagent Pharmaceuticals, Pfizer, West-Ward Pharmaceuticals
-
Subject:
-
Document Type:
-
Place as Subject:
-
Collection(s):
-
Main Document Checksum:
- File Type:
-
Supporting Files:No Additional Files
No Related Documents.
Email
CDC-INFO
